Document text
Principal Investigator: Sean Agbor-Enoh
Organization: NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
Fiscal Year: 2024
Award: $2,159,104
Funding agency: National Heart Lung and Blood Institute
Project 1: Cell-free DNA to detect acute rejection. Dr. Agbor led the creation of the Genomic Research Alliance for Transplantation (GRAfT), a consortium of five transplant centers in the DC metropolitan area and NHLBI. He is the principal investigator of the natural history study of heart and lung transplant patients. The GRAfT study recruits patients on the transplant wait list. After transplantation, patients are monitored closely with collection of clinical data and serial samples. Sample collection include plasma, blood cells, and fluid from the transplanted lung. The samples are processed at the study sites and transferred to NHLBI for storage and experimentation.
Dr. Agbor leveraged transplant genomic admixture to identify and quantitate donor-derived cell-free DNA (ddcfDNA)as a non-invasive and reliable biomarker of allograft injury. Cell-free DNA are short DNA fragments release when cells die into the circulation. During transplant rejection, allograft cells die and release ddcfDNA into the recipient circulation. Since the donor and recipient has different DNA sequences, ddcfDNA can be quantified in recipients blood as a marker of rejection. Dr. has shown that ddcfDNA is sensitive but non-specific for acute rejection. ddcfDNA also detects rejection earlier, up to 2 to 3 months before biopsy. His lab, the Laboratory of Applied Precision Omics (APO) has defined the test characteristics of ddcfDNA and has established a ddcfDNA algorithm that can be used to monitor patients after transplantation, setting the stage for a clinical utility trial. Additional studies have shown that early post-transplant ddcfDNA levels reliably stratify patients for risk of subsequent chronic rejection and early death. APO has also defined racial disparities in chronic rejection and early death. APO has since developed a 2nd generation cfDNA approach that has applications beyond transplantation, showing good performance at defining COVID-19, pulmonary arterial hypertension outcomes. APO is testing if the 2nd generation test can distinguish the different types of rejection.
Project 2: Identifying novel and effective drug targets for rejection. APO showed that 75% of patients with one type of rejection fail to respond to treatment and progress to develop chronic CLAD. APO aims to identify molecular mechanisms of treatment failure and has leveraged the GRAfT biorepository to analyze samples. APO intend to compare patients who respond well to treatment to patients who are non-responders. The preliminary analysis showed distinct molecular mechanisms: complement activating pathways for responders versus antibody-mediated phagocytic pathways that utilize the spleen tyrosine kinase (Syk) as a downstream mediator for non-responders. Syk has FDA-approved inhibitors such as Fostamatinib. APO is initiating a series of studies to test the efficacy of fostamatinib to treat antibody-mediated rejection. In addition, APO will use single-cell multi-omics approaches to validate these findings and identify additional drug targets and then test the clinical utility of these additional treatment.
Project 3: Leverage GRAfT consortium for pilot clinical utility studies. The GRAfT is a collaborative with a robust clinical research infrastructure at each center. APO leverages the GRAfT consortium to pilot the clinical utility of novel diagnostic tools or targeted therapies. The first study is the Analysis of Lung Allograft Remote Monitoring (ALARM 1.0). This is completed and results are published. The study included 175 subjects with 350 ddcfDNA tests and demonstrated that monthly cfDNA monitorig instead of bronchoscopy is safe. ddcfDNA demonstrated good performance to detect rejection and infection similar to cohort studies. APO is now setting up the Syk Inhibition in MItigating Lung Allograft Rejection (SIMILAR) trial, a pilot RCT to test the safety and efficacy of a Syk inhibitor Fostamatinib versus placebo as an adjunct therapy for rejection.
Terms: <Acute><Admixture><Algorithms><Allografting><Antibodies><Area><Biological Markers><Biopsy><Blood><Blood Cells><Blood Plasma><Blood Reticuloendothelial System><Bronchoscopy><COVID-19><CV-19><Cardiac Transplantation><Caring><Cause of Death><Cell Body><Cells><Cessation of life><Characteristics><Chronic><Circulation><Clinical><Clinical Data><Clinical Research><Clinical Study><Cohort Studies><Collection><Complement><Complement Proteins><Concurrent Studies><Coronavirus Infectious Disease 2019><DNA><DNA Sequence><Death><Deoxyribonucleic Acid><Diagnosis><Drug Targeting><Dysfunction><Environment><FDA approved><Functional disorder><Generations><Genetic><Genome><Genomics><Goals><Graft Rejection><Grafting Procedure><Heart Grafting><Heart Transplantation><Histopathology><Hospitals><Immunochemical Immunologic><Immunologic><Immunological><Immunologically><Immunologics><Infection><Injury><Inter-Observer Variability><Inter-Observer Variation><Interobserver Variability><Interobserver Variations><Laboratories><Life><Liquid substance><Lung Diseases><Lung Grafting><Lung Transplantation><Mediating><Mediator><Mission><Molecular><Monitor><NHLBI><National Heart, Lung, and Blood Institute><Natural History><Organ><Organ Transplantation><Organ Transplants><Outcome><PTK Inhibitors><Pathway interactions><Patient Monitoring><Patient Recruitments><Patient risk><Patients><Performance><Peripheral Blood Cell><Phagocytes><Phagocytic Cell><Physiopathology><Placebos><Plasma><Plasma Serum><Prevention><Principal Investigator><Process><Protein Tyrosine Kinase Inhibitors><Publishing><Pulmonary Diseases><Pulmonary Disorder><Pulmonary Graft><Pulmonary Transplant><Pulmonary Transplantation><Research><Research Infrastructure><Reticuloendothelial System, Serum, Plasma><Risk Factors><SYK><SYK gene><Sampling><Series><Sham Treatment><Site><Solid><Spleen Tyrosine Kinase><TK Inhibitors><Testing><Transplant Recipients><Transplant Rejection><Transplantation><Transplantation Rejection><Treatment Failure><Tyrosine Kinase Inhibitor><Tyrosine-Protein Kinase SYK><Waiting Lists><allograft rejection><amebocyte><antibody rejection><antibody-mediated rejection><bio-markers><biobank><biologic marker><biomarker><biorepository><cardiac graft><cell free DNA><cell free circulating DNA><complementation><coronavirus disease 2019><coronavirus disease-19><coronavirus infectious disease-19><diagnostic tool><disease of the lung><disorder of the lung><disparities in race><disparity due to race><effective therapy><effective treatment><efficacy testing><fluid><heart transplant><improved><inequality due to race><inequity due to race><inhibitor><injuries><liquid><lung allograft><lung disorder><lung transplant><metropolitan><multiomics><multiple omics><new diagnostics><next generation diagnostics><novel><novel diagnostics><organ allograft><organ graft><organ xenograft><panomics><participant enrollment><participant recruitment><pathophysiology><pathway><patient enrollment><patient population><patient stratification><post-transplant><post-transplantation><posttransplant><posttransplantation><programs><pulmonary arterial hypertension><pulmonary artery hypertension><race based disparity><race based inequality><race based inequity><race disparity><race related disparity><race related inequality><race related inequity><racial disparity><racial inequality><racial inequity><racially unequal><remote monitoring><response><safety testing><sample collection><sham therapy><specimen collection><stratified patient><targeted drug therapy><targeted drug treatments><targeted therapeutic><targeted therapeutic agents><targeted therapy><targeted treatment><therapy failure><transplant><transplant centers><transplant patient><waitlist>